drugset

drugset / Trial / NCT00404300

Optivate in People With Von Willebrand Disease Undergoing Surgery

NCT00404300 ↗

Phase 3 Terminated 25 enrolled Bio Products Laboratory

Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open, multi-centre study in patients with von Willebrand Disease (VWD) undergoing surgery.

Timeline

Start: 2007-02
Primary completion: —
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Factor VIII	Protein / enzyme biologic	—	—

Indications